Advances in pyruvate kinase M2 in the diagnosis treatment and prognosis of gastric cancer
1Wang Daoyu，2Huang He
1First Clinical Medical School of Shanxi Medical University Taiyuan 030001 Shanxi China
2Department of General Surgery First
Hospital of Shanxi Medical University Taiyuan 030001 Shanxi China
Abstract：Gastric cancer is a malignant tumor with the highest incidence and mortality rate and low 5-year survival rate in China.
Treatment of gastric cancer is mainly surgery combined with radiation and chemotherapy. Due to the inconspicuous early symptoms of
gastric cancer and the limited sensitivity and specificity of the current traditional tumor markers it is difficult to diagnose patients with
early gastric cancer in China. Therefore the diagnostic pathways of early gastric cancer the targets of gastric cancer treatment and effective prognostic assessment methods have been major concerns. In recent years key enzymes in the energy metabolism of tumor cells
have received more attention. Pyruvate kinase M2 PKM2 a key enzyme in the glycolytic pathway is abnormally expressed in tumor
tissues serum and other body fluids and is involved not only in the nutrient metabolism of tumor cells but also in mitogenic activation. It is not only involved in the transcription of MAPK but also related to phosphatidylinositol-3-kinase PI3K / protein kinase B/
the mammalian target of tapamycin mTOR PI3K/ Akt / mTOR signaling pathway and NF-κB/ miR-148a / 152 feedback loop and
other processes and through the above responses promote the proliferation invasion metastasis and vascular tumorigenesis of gastric
cancer cells and inhibit apoptosis of gastric cancer cells. Recent researches have shown that PKM2 can be used for early diagnosis
treatment and prognosis assessment of gastric cancer. This study reviews researches about early diagnosis treatment and prognosis assessment of PKM2 in gastric cancer in recent years which provide insight for improving the sensitivity and specificity of diagnosis developing new treatment strategies and prognosis assessment.
收稿日期: 2022-01-21
通讯作者:
黄 河,电子邮箱:hh93003@163.com
引用本文:
1王道煜,2黄 河. 丙酮酸激酶 M2 在胃癌诊治和预后中的研究进展[J]. 肿瘤代谢与营养电子杂志, 2022, 9(3): 396-400.
1Wang Daoyu，2Huang He. Advances in pyruvate kinase M2 in the diagnosis treatment and prognosis of gastric cancer. Electron J Metab Nutr Cancer, 2022, 9(3): 396-400.
